Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 5, 2006, Pages 618-625

  Hurtubise, Annie ^a   Momparler, Richard L ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

5 Aza 2 deoxycytidine; Breast cancer; DNA methylation; Dose schedule; Histone deacetylase inhibitor; LAQ824

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL CYCLE S PHASE; CELL STRAIN MCF 7; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; EPIGENETICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR GROWTH;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; S PHASE; TIME FACTORS; TUMOR STEM CELLS;

EID: 33746679765     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0225-6     Document Type: Article

References (26)

1. Archer SY, Hoddin RA (1999) Histone acetylation and cancer. Curr Opin Genet Dev 9:171-174
2. Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A, Remiszewski S (2004) Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64:689-695
3. Baylin SB (2002) Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol 12:331-337
4. Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, Baylin SB (2003) Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 63:7089-7093
5. Bovenzi V, Momparler RL (2001) Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol 48(1):71-76
6. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107
7. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495-528
8. Garcia-Manero G, Issa J-P (2005) Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest 23:635-642
9. Gilbert J, Gore SD, Herman JG, Carducci MA (2004) The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 10:4589-4596
10. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640
11. Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163-167
12. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216
13. Maslak P, Channel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I, Warrell R, Nimer S (2006) Pilot study of combination of transcriptional modulation therapy with sodium phenylbutyrate and 5-azacitidine in patients with acute myeloid leukemia ore myelodysplastic syndrome. Leukemia 20:212-217
14. Momparler RL, Samson J, Momparler LF, Rivard GE (1984) Cell cycle effects and cellular pharmacology of 5-AZA-2′-deoxycytidine. Cancer Chemother Pharmacol 13:191-194
15. Momparler RL, Bovenzi V (2000) DNA methylation and cancer. J Cell Physiol 183:145-154
16. Momparler RL, Ayoub J. (2001) Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34:S111-S115
17. Momparler RL (2005) Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Semin Hematol 42(3 Suppl 2):S9-S16
18. Primeau M, Gagnon J, Momparler RL (2003) Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer 103:177-184
19. Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P (2003) N-hydroxy-3-phenyl-2- propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H- indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 46:1609-1621
20. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R (1991) The antileukaemic activity of 5-Aza-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br J Cancer 64:144-148
21. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin K, Momparler LF (1981) Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 5:453-462
22. Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, Carducci MA, Baker SD (2005) Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with solid tumors or haematological malignancies. J Clin Oncol 23:3906-3911.
23. Sanchez-Gonzales B, Yang H, Cuadros M, Santos-Malave C, Hoshino K, Kantarjian H, Issa JP, Garcia-Manero G (2005) In vivo molecular implications of the combination of the hypomethylating agent 5-aza-2′-deoxycytidine and the histone deacetylase inhibitor valproic acid in patients with leukemia: results of a phase I/II study. Proceeding AACR 46:937 (#3979)
24. Schrump DS, Nguyen DM, Kunst TE, Hancox A, Figg WD, Steinberg SM, Pishchik V, Becerra Y (2002) Phase I study of sequential deoxyazacytidine/ depsipeptide infusion in patients with malignancies involving lung or pleura. Clin Lung Cancer 4(3):186-192
25. Wolffe AP (1996) Histone deacetylase: a regulator of transcription. Science 272:371-372
26. http://www.clinicaltrials.gov/ct/show/NCT00101179 MS-275 and Azacytidine in treating patients with myelodysplastic syndromes, chronic myelomonocytic leukemia or acute myeloid leukemia. NCT00101179